Wei X.-C.,Institute of Hematological Research |
Yang D.-D.,Institute of Hematological Research |
Han X.-R.,Institute of Hematological Research |
Zhao Y.-A.,Institute of Hematological Research |
And 3 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015
Objective: We investigated the effect of umbilical cord blood dendritic cells (DCs) on in vitro proliferation, immunophenotypes and levels of homologous cytokine-induced killer cells (CIK) and the toxicity on leukemia cells. Method: Mononuclear cell-induced DC-CIK cells derived from umbilical cord blood were collected and co-cultured in the proportion of 1:5. Cord blood CIK cells or peripheral blood DC-CIK cells were used as control. Phenotypes were analyzed by flow cytometry; vial cell counting was performed using trypan blue, and the killing activity of effector cells against leukemia cells was measured by MTT assay. The levels of interferon-r (IFN-r), tumor necrosis factor-a (TNF-α) and interleukin-12 (IL-12) were determined by ELISA. Results: The proliferative capacity of DC-CIK cells was obviously improved compared with cord blood CIK cells and peripheral blood DC-CIK cells (P<0.05, P<0.05). During the co-culture of cord blood DC-CIK cells, the ratios of CD3 +CD8 + and CD3 +CD56 + cells were obviously higher than that of CIK cells under the same conditions (P<0.05). On day 3 of co-culture, the levels of IL-12, IFN-r and TNF-a in cultured supernatant of cord blood DC-CIK cells were all higher than those secreted by CIK cells cultured alone (P<0.01, P<0.05, P<0.05). When the effector to target ratio was 2.5-20:1, the killing effect of cord blood DC-CIK cells against each subtype of acute leukemia cells was obviously higher than that of CIK cells (P<0.05). No significant differences in killing effect were observed for different subtypes. This finding was consistent with the killing effect of peripheral blood DC-CIK cells against leukemia cells. Conclusion: Cord blood DCs can enhance the proliferative capacity of homologous CIK cells and its anti-leukemia effect. Though cord blood DC-CIK cells showed a higher proliferative capacity than peripheral blood DC-CIK cells, the two types of DC-CIK cells did not differ significantly in terms of cytoxicity. With a high availability and the low probability of graft rejection reaction, cord blood DC-CIK cells have a brighter prospect for application in immunotherapy. © 2015, E-Century Publishing Corporation. All Rights Reserved. Source
Wei X.C.,Institute of Hematological Research |
Yang D.D.,Institute of Hematological Research |
Han X.R.,Institute of Hematological Research |
Zhao Y.A.,Institute of Hematological Research |
And 3 more authors.
Genetics and Molecular Research | Year: 2015
We investigated the roles of CD3McAb and rhIL-2 activated bone marrow in the killing and purging of leukemia cells. Cytotoxicity of activated bone marrow was detected with MTT assay. CFU-GM level in activated bone marrow and the destruction of leukemia cells were measured using the semi-solid cell culture. Immune activation markers in activated bone marrow were detected by indirect immunofluorescence assay. Bone marrow activated by CD3McAb and rhIL-2 displayed significantly upregulated the killing and purging abilities on the leukemia cell line K562 and HL-60. Such effects were superior to that of bone marrow activated by rhIL-2 or CD3McAb alone (P < 0.05, P < 0.01). Activation by rhIL-2 and (or) CD3McAb exerted no obvious influence on CFU-GM level in bone marrow. Compared with bone marrow activated by rhIL-2 or CD3McAb alone, the synergistic effect of both CD3McAb+ and hIL-2 caused significant increase of CD3+, CD8+, CD19+, CD25+, CD38+, and CD56+ levels. Our study indicates that CD3McAb enhanced the killing and purging effects of rhIL-2 activated bone marrow on leukemia cells. © FUNPEC-RP. Source